We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Natural nuclear receptor ligands
- Vitamins and steroids as nuclear receptor ligands
- Nuclear receptors and nuclear receptors ligands
- Negative feedback mechanisms
- Lipid and metabolite sensing nuclear receptors
- Xenobiotic sensors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Merk, D. (2026, October 29). Natural ligands of nuclear receptors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 29, 2026, from https://doi.org/10.69645/IAQV5039.Export Citation (RIS)
Publication History
- Published on October 29, 2026
Financial Disclosures
- Daniel Merk discloses affiliations with Ludwig-Maximilians-University Munich and the Free State of Bavaria. He is a member of the German Pharmaceutical Society (DPhG) and the German Chemical Society (GDCh). He has received honoraria for lectures, authoring, reviewing, and advisory activities from the DPhG, German Associations of Pharmacists, German Medical Association, Sanofi, Boehringer Ingelheim, ONO Pharmaceuticals, YS Life Science, AVOXA, SpringerNature, Wiley, and the Swiss National Science Foundation (SNF). Additionally, he holds five patents or patent applications related to nuclear receptor modulators and other small molecule drugs. His research is funded by the European Research Council (ERC), Innovative Medicines Initiative (IMI), German Research Foundation (DFG), German Federal Agency for Disruptive Innovation (SPRIN-D), and Immunic AG.
Other Talks in the Series: Nuclear Receptors as Common Therapeutic Targets
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome, everyone,
to Chapter 7 of
this short talk series on
nuclear receptors as
therapeutic targets.
After discussing the molecular
activation mechanisms
by ligands in the last chapter,
this chapter will now cover
the natural ligands of nuclear
receptors and their roles.
0:19
Based on the
knowledge of ligands,
nuclear receptors can be
classified into four groups,
as shown here by the
different colors.
The classification has
also historical reasons
and somewhat reflects
when the natural ligands
for each receptor
were discovered.
Classic nuclear
receptors are receptors
whose ligands were discovered
early in nuclear
receptor research.
This includes steroid
hormone receptors of
the NR3 family and some
members of the NR1 family,
namely the thyroid
hormone receptors,
the retinoic acid receptors,
and the vitamin D receptor.
These receptors are all
named by their ligands.
Nuclear receptors for which
a natural ligand was
initially lacking
but could later be
clearly assigned are
often described or
classified as foster home.
The names of these receptors
refer mostly to the site
or tissue where they
were first discovered
or to a biological role.
The natural ligands
were often discovered
in early
crystallographic studies
on the respective receptors.
This class comprises
several metabolic sensors
that bind endogenous
metabolites:
peroxisome proliferator-activated
receptors,
the NR1C family,
and hepatocyte nuclear
factors, the NR2A family,
bind fatty acids and metabolites
as endogenous ligands.
Retinoic acid receptor-related
orphan receptors,
the NR1F family, bind
cholesterol metabolites,
and the NR5A family receptors
liver receptor homologue-1
and steroidogenic factor-1
are phospholipid sensors.
The pregnane X receptor and
the constitutive
androstane receptor
have a special role
in this class,
as they bind diverse types of
ligands summarized
as xenobiotics.
We will have a closer look
at their role later
in this chapter.
Also, the so-called adopted
orphan nuclear receptors
were initially described
without known ligands,
and the endogenous modulators
were identified later.
This class includes the
revERB proteins binding heme,
the liver X receptors as
sensors for cholesterol
metabolites,
the farnesoid X receptor
which binds bile acids,
and the retinoid X
receptors for which
9-cis retinoic acid
has been identified
as a high-affinity
natural ligand.
However, some of the bona
fide natural ligands
of adopted orphans
are still debated.
For example, 9-cis retinoic acid
strongly activates the RXRs,
but it is not clear
whether natural levels of
these molecules are high enough
to cause relevant
RXR modulation.
The retinoid X receptors
also bind other vitamin A
and fatty acid metabolites
which may hence be
more relevant as
endogenous ligands.
The fourth class comprises
the so-called orphan
receptors for which
the endogenous ligands
have not been assigned.
However, the level of knowledge
on ligands in this
class varies strongly.
For some receptors,
ligands remain
completely elusive,
whereas for others several
natural ligand candidates
have been identified but not yet
clearly confirmed as
endogenously relevant.
We will discuss this
in more detail in
later chapters on the
individual receptors.
It should be noted that
the classification
in classic nuclear
receptors, foster home,
adopted orphans, and
orphans is not absolute
but dynamic and has
blurry boundaries.
Natural nuclear receptor ligands